DMT

Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents
DEA Raises THC, Psilocybin And DMT Production Quotas For Scientific Research Purposes
More Protocols And Guidance Are Needed As Momentum Builds For Veterans, Psychedelics, And Mental Health
DEA Raises THC, Psilocybin And DMT Production Quotas For Scientific Research Purposes
More Protocols And Guidance Are Needed As Momentum Builds For Veterans, Psychedelics, And Mental Health
Psychedelics In Mexico: Are They Legal? Well, Yes And No
Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business

DMT Recent News

Study Sheds Light On How A Brain On Ayahuasca's Psychedelic Component Looks
A new study reveals the most advanced-to-date brain images of the effects of the psychedelic compound DMT.
DMT VS. Psilocybin: Are We All Experiencing The Same Trip?
This article was originally published on Psychedelic Spotlight and appears here with permission. DMT and psilocybin are both powerful elements of Mother Nature's alchemy, but do they offer an identical journey? Let’s explore to find out.
Cybin Approved For First In-Human Dosing Of DMT Molecule CYB004, Milestone For Anxiety Disorder Treatment
Cybin Inc. (NYSE: CYBN) announced that it has received approval from an independent ethics committee in the Netherlands to begin the first in-human dosing of its proprietary deuterated N, N-dimethyltryptamine (DMT) molecule CYB004 through a protocol amendment to its ongoing CYB004-E Phase 1 trial. 
Top 3 Psychedelic Storylines To Watch In 2023
This article by James Hallifax was originally published on Microdose and appears here with permission.
EXCLUSIVE: Defining 'Natural' Psychedelics, State Regulations & Ayahuasca's Benefits
(Part three of a three-part series) See previous stories: EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing
Canadian clinical-stage psychedelics company Algernon Pharmaceuticals (OTCQB: AGNPF)’s newly created subsidiary Algernon NeuroScience (AGN Neuro) has dosed
Ayahuasca's Benefits Outweigh Risks, A New Australian Study Finds
In Australia, a new study conducted by the University of Melbourne analyzed data from an Online Global Ayahuasca Survey conducted between 2017 and 2019 that showed 10,836 people over the age of 18 had
This Novel Short-Acting Psychedelic Compound Is Ready For First Phase 1 Clinical Try-Out
Small Pharma Inc.
A Foundational Study On Stroke Is Ready. Here Is Why It's Important
Biopharma company Algernon Pharmaceuticals Inc's (OTC: AGNPF) recently announced plan for a Phase 1 clinical study on DMT for huma
DMT Producer PsyBio And Shrooms Grower Red Light Holland Share Their Most Recent Financial Results
PsyBio Therapeutics (TSXV: PSYB) (OTCQB: PSYBF), a biotech developing medicines based on naturally-occurring psychedelic substances, and mushroom producer Red Light Holland Corp. (OTC Pink: TRUFF) announced the
Science Feature: Next-Generation Psychedelics
This article was originally published on Microdose and appears here with permission.
Is Smoking DMT Safe?
This article was originally published on Psychedelic Spotlight and appears here with permission. DMT is a popular hallucinogen being studied for its therapeutic potential, but is smoking DMT safe? Here’s everything you need to know.
Encountering DMT Entities: Are They Real?
This article was originally published on Psychedelic Spotlight and appears here with permission. DMT is a powerful hallucinogen famous for producing experiences of encounters with entities, but how many people actually see them?
A Deeper Look At DMT Trials & Studies
This article by Elisabetta Fato was originally published on Microdose and appears here with permission.
EXCLUSIVE: How Cybin Is Developing The Next Generation Of Psychedelics
If you’re just now considering the therapeutic value of psychedelics, Cybin Inc (NYSE: CYBN) is many trips ahead of you.
Extending the Experience: Interview With DMT Pioneer Rick Strassman
Top 5 Most Influential Psychedelic Studies
Forget Shrooms, Is Toad Venom The New Hallucinogenic Drug For The Rich And Famous?
This article was originally published on Cannabis.net and appears here with permission. It’s 2022, and we’re decades away from the 60’s but psychedelics sure are having another hey day.
DMT Vape Pen Patent Illustrates A Big Problem In The Psychedelics Industry
This article was originally published on Psychedelic Spotlight and appears here with permission.
Inside A 5-MeO-DMT Retreat: Who Should And Shouldn't Embark On This 'Hero's Journey'
This article was originally published on Psychedelic Spotlight and appears here with permission.
Cybin Receives U.S. Patent For Its Proprietary DMT Compound To Treat Anxiety Disorders
Psychedelics company Cybin Inc. (NEO: CYBN) (AMEX: CYBN) announced that the U.S. Patent and Trademark Office has granted U.S. patent 11,242,318 to the company’s investigational deuterated dimethyltryptamine (“DMT”) compound CYB004.
Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient
Psychedelics biotech startup Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) announced the approval by the local Dutch ethics committee for a Phase 1 clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of the psychedelic compound DMT.
A Deeper Look At DMT, The 'Spirit Molecule'
This article was originally published on Microdose and appears here with permission.